Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07222995 · ClinicalTrials.gov registry record · NA

Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs

A NA study of Skin Cancer, sponsored by H. Lee Moffitt Cancer Center and Research Institute.

Recruiting
Registry status
NA
Development phase
2,900
Enrollment target
2
Study locations

NCT07222995 is a NA study of Skin Cancer that is actively recruiting participants, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 2,900 participants, above the 392-participant average among 40 other Skin Cancer trials with a reported enrollment target (640% higher). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07222995, a NA study of Skin Cancer, is actively recruiting participants, sponsored by H. Lee Moffitt Cancer Center and Research Institute.

RECRUITING
Registry status
NA
Development phase
2,900 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to examine how different messages about risk of skin cancer can impact the uptake of skin cancer prevention activities.

Conditions Studied

Interventions

  • BEHAVIORAL Precision Prevention Booklet
  • BEHAVIORAL Standard Prevention Booklet

Study Locations (2)

Florida

  • Moffitt Cancer Center - Tampa

New York

  • Memorial Sloan Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 2,900 participants
Start Date 2025-10-10
Est. Completion 2030-10-10
Phase NA

What the Registry Record Tells You About NCT07222995

The ClinicalTrials.gov registry entry for NCT07222995 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 2,900 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 392-participant average among 40 other Skin Cancer trials with a reported enrollment target (640% higher). The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Skin Cancer appearing as the primary indexed condition, and to 2 interventions - of which Precision Prevention Booklet is the first listed.

NCT07222995 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, New York.

Frequently Asked Questions

What is clinical trial NCT07222995 about?

NCT07222995 is a clinical study titled "Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs". The purpose of this study is to examine how different messages about risk of skin cancer can impact the uptake of skin cancer prevention activities.

What is the current status of trial NCT07222995?

This trial is currently recruiting. It is a NA study. The enrollment target is 2,900 participants. The study started on 2025-10-10. Estimated completion is 2030-10-10.

What conditions does trial NCT07222995 study?

This clinical trial studies the following conditions: Skin Cancer.

What interventions are being tested in trial NCT07222995?

The interventions under investigation include: Precision Prevention Booklet (BEHAVIORAL), Standard Prevention Booklet (BEHAVIORAL).

Who is sponsoring clinical trial NCT07222995?

This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07222995 being conducted?

This trial has 2 study locations across Florida, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Skin Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.